Introduction: Irritable bowel syndrome (IBS) is a part of the larger group of functional gastrointestinal (GI) disorders that despite differences in location and symptom patterns share common features with regard to their motor and sensory physiology and central nervous system relationships. It generates a significant health care burden and can severely impair quality of life. It is characterized by symptoms of abdominal pain and discomfort that is associated with disturbed defecation. Ayurveda compares the symptoms of IBS with some of the diseases like Grahani, Kaphaja Pravahika, Shokaja Atisara, Bhayaja Atisara, etc. Bilvadi Leha and Kutajarishta are two common Ayurvedic formulations that are currently used for the management of such diseases. However, the safety of these drugs was not evaluated until now.
INTRODUCTION
Irritable bowel syndrome is a GI disorder characterized by altered bowel habits in association with abdominal discomfort or pain in the absence of detectable structural and biochemical abnormalities. 1 It basically happens due to alteration in GI motility, secretion, and sensation. 2, 3 The symptomatic analysis of IBS, points to Grahani, Kaphaja Pravahika, Shokaja Atisara, Bhayaja Atisara, etc., mentioned in Ayurveda classics which are characterized by altered bowel habits and other GI symptoms. The pathogenesis of Grahani 4 begins with the vitiation of Agni (digestive fire) in terms of its quality, quantity, and function. All metabolic physiological transformations in the body are carried out under the influence of Agni. Mandagni (quantitative, qualitative, and functional decrease of Agni) is the root cause of Ama Dosha, and it is a crucial factor for manifestation of most of the diseases. 5 Ama Dosha, resulting from Mandagni, plays a pivotal role in the pathogenesis of GI disorders, such as Grahani Roga, Bhayaj Atisara, Shokaj Atisara, etc. Vitiation of Samana and Apana Vayu affects the enteric nervous system, alters the GI motility and hormone activity producing the symptoms of Grahani. All these diseases have psychological factors, such as fear and anxiety as etiology, and IBS also has psychological factors responsible for its origin. The modern IBS therapies include bulk-forming agents, antidiarrheal, antispasmodics, antidepressants, JRAS etc., which lack demonstrable efficacy. While considering the cost and potential risks (severe constipation, severe diarrhea, ischemic colitis) against potential benefits, potential risks outweigh the possible benefits. 6 Therefore, exploring alternative medicines for therapeutic options, which are effective, economical, and safe, is needed. Bilvadi Leha and Kutajarishta are two of the drugs used in diseases which are symptomatically similar to IBS and have been practiced by many practitioners. This set of studies was done to analyze the safety of Bilvadi Leha and Kutajarishta in IBS.
Drug Profile
The drugs that act on regulating the Agni and movement of Koshta must contain the following properties: Agnideepana (enhancing the digestive activity), Amapachana (eliminating undigested metabolic products), Vata Anulomana (regulating samana and apana and normalising its activity) and should act at the level of Kostha and modulate the altered GI activity. Bilvadi Leha was given as the dose of 10 gm BD with lukewarm water after food (trial 1) and Kutajarishta was given as 25 mL BD with equal amount of water after food (trial 2). Follow-up was done every 2 weeks in both the trials to record the onset of any adverse reaction during the intervention. Total intervention period was 12 weeks. The data obtained from the completed clinical studies were analyzed retrospectively to assess the safety profile of Bilvadi Leha and Kutajarishta through LFTs and KFTs.
Statistical Analysis
Data of LFTs and KFTs collected at the beginning and at the end of the trial period were compared using paired t-tests. A p-value <0.05 was considered significant. Clinical symptoms have been reported as n (%) and have been compared as percentage change before and after the treatment.
OBSERVATION AND RESULTS

Bilvadi Leha
A total of 171 patients were enrolled in study I entitled Clinical Evaluation of Bilvadi Leha in the Management of IBS of which 22 patients dropped out in the course of the study. Among the total dropouts, 8 were not included for analysis. Last observation carried forward was applied on 14 patients who had completed at least two visits. Thus, data of 163 (171 -22 + 14) patients were used for analysis. Among the dropout patients, no one quit the study for the reason of drug's safety or palatability issues, so it is clear that the medicine had not any adverse effect on their health.
Among the total analyzed 163 patients, 66.9% were males and remaining 33.1% were females. The mean age of 163 patients was observed to be 42.88. Total 54% of the patients hailed from urban area. Maximum number of patients (47.8%) was doing desk work with less physical activity, and 84% were above poverty line. About 92.6% of the patients were able to read and write. The history of stress was identified in 50.9% of patients, and 55.8% of the population were vegetarian. Irregular bowel habits were seen in 92.0% patients. Loose stool consistency was seen in 67.5% cases.
Effect of Bilvadi Leha on disease-specific symptoms, IBS severity score, and WHO quality of life (QOL)-BREF score was statistically significant (p-value < 0.001). Chronic or recurrent abdominal discomfort was present in 90.8% of cases at baseline, and after completion of treatment it remained only in 26.4%. Likewise, abdominal bloating was present in 89.6% cases at the baseline, which was reduced to 42.3% at the end of day 84. No significant adverse events or adverse reactions were observed during the study. Both, the LFTs and KFTs were found to be in normal limits before and after the trial.
Kutajarishta
A total of 180 patients were enrolled in the study entitled Clinical Evaluation of Kutajarishta in the Management of IBS of which 10 patients dropped out in the course of the study. Last observation carried forward was applied on 8 patients who had completed at least two visits. Thus, data of 178 (180 -10 + 8) patients was used for analysis. The dropout patients were not included in the study, as they could not turn up for follow-up in time due their prior engagement out of the city. One patient reported increased frequency of bowels and did not continue the study.
Among those 178 patients, majority of patients were under the age group from 39 to 48 years, i.e., 37.6% (67 patients). About 60.7% of them were males and remaining 39.3% were females. Total 92.7% were literate, and majority of them were having desk work. Also, 92.7% of them were having good socioeconomic status. Urban area-residing patients were 68.5%. Among the total, 68% of the patients were vegetarian. Major symptoms noted in the patients were irregular bowel habits in 81.5% cases and loose stools in 81.5% cases. Effect of Kutajarishta on chief complaints, disease-specific symptoms, IBS severity score, and WHO QOL-BREF score was highly significant (p < 0.001), for example, chronic or recurrent abdominal discomfort or pain was present in 99.4% of cases at baseline, and after completion of treatment it was present in 24.7% of cases. Likewise, urgency of bowel movements was present in 86.5% cases at the baseline, which was reduced to 16.3% at the end of day 84. No significant adverse events or adverse reactions were observed during the study. Both, the LFTs and KFTs were found to be in normal limits before and after the trial. The data regarding demographic profile are given in Table 1 , and safety parameters obtained from the three centers are given in Table 2 and Graphs 1 to 4.
DISCUSSION
Irritable bowel syndrome is a functional GI disorder characterized by abdominal pain or discomfort, altered On analysis, it was observed that majority of IBS patients were having desk work with minimal physical activity as their profession. Physical inactivity may have an indirect role in altering the intestinal motility and may lead to apana vayu vaigunya in koshtha producing alteration in bowel habits. The disease was found mostly in residents of urban region, which may be due to the unhealthy dietary habits and stressful life. Common symptoms manifested were chronic or recurrent abdominal discomfort or pain, abdominal bloating, urgency of bowel movements, feeling of incomplete evacuation, passage of mucous, straining, distension of abdomen, etc., due to agnimandya leading to ama formation, which causes obstruction (srotoavarodha) in the GI pathways. The IBS is a disease that responds well with proper alterations in diet (using food that are easily digestible without stress to GI tract), physical activity and with decrease in stress levels. But, once the disease manifests, maintenance of Agni and Vatanulomana is the right path to relieve symptoms. In these studies, significant changes were noticed in the qualitative parameters, like Udar Shool (pain in abdomen), diarrhea, chronic or recurrent abdominal discomfort, abdominal bloating, feeling of incomplete evacuation, etc. The safety profile was analyzed through comparing the changes in LFTs and KFTs before and after the trial duration. Drug compliance and development of adverse effects/adverse drug reactions, if any, were scrutinized. In-depth observations revealed that there was not any change in the safety parameters like blood urea, serum uric acid, serum creatinine, total protein, serum globulin, serum albumin, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and bilirubin levels in the body. All these parameters were found to be within the stipulated range after treatment also. Hence, it can be concluded that Bilvadi Leha and Kutajarishta are safe and effective in IBS.
CONCLUSION
Irritable bowel syndrome is a condition that significantly affects the quality and productivity of life. Nidana Parivarjana and synchronizing the harmonious activity of Agni and Vata in the intestine are the key factors in managing IBS. Kutajarishta and Bilvadi Leha act by regulating the activity of Doshas and Agni in Koshta. From this study, it can be concluded that in spite of the differences in gender, socioeconomic status, age group, Prakrti, and geographic region, Kutajarishta and Bilvadi Leha proved to be very much safe, effective, and tolerable in the management of IBS. No adverse reactions or adverse events pertaining to drug interaction were noticed during the trial period.
